GlassScriptPhysician profile
Colin M Roberts
NPI 1295743722
$18,626.38
in general payments reported to CMS, 2019-2025
15 companies · $2,225 in 2025
The $2,225 reported for 2025 was more than what 80% of Neurology With Special Qualifications In Child Neurology providers received nationally (typical 2025 total: $275).
See the full distribution for Neurology with Special Qualifications in Child Neurology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $9,648 · 2020: $1,050 · 2021: $3,895 · 2022: $483 · 2023: $984 · 2024: $341 · 2025: $2,225.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,970 · Food and Beverage: $580.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,970.00 |
| Food and Beverage | $580.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Greenwich Biosciences, INC. | $13,192.65 | 2019-2021 | |
| Neurelis, INC. | $3,226.08 | 2022-2025 | Valtoco |
| Zogenix INC. | $1,400.00 | 2021 | |
| Jazz Pharmaceuticals INC. | $349.10 | 2022-2024 | |
| Ucb, INC. | $251.73 | 2022-2025 | Fintepla |
| Biocodex, INC. | $80.82 | 2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $67.75 | 2022-2023 | |
| Immedica Pharma US, INC. | $38.83 | 2024 | |
| Medtronic, INC. | $19.42 | 2022 |
6 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Colin Roberts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.